FOLH1 and neoplasm: Conversely, the pyridyl derivative [18F]DCFPyL (2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) showed a higher binding affinity for PSMA and tumor uptake, and lower blood persistence than [18F]DCFBC, with an overall suitable profile for use in humans (Chen et al., 2011).